Annabel McMillan

1.4k total citations · 1 hit paper
22 papers, 941 citations indexed

About

Annabel McMillan is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Annabel McMillan has authored 22 papers receiving a total of 941 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 10 papers in Oncology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Annabel McMillan's work include Multiple Myeloma Research and Treatments (10 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Annabel McMillan is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Lymphoma Diagnosis and Treatment (9 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Annabel McMillan collaborates with scholars based in United Kingdom, Italy and United States. Annabel McMillan's co-authors include David C. Linch, D. J. Moir, A. H. Goldstone, Rajesh Chopra, D.A. Winfield, Barry W. Hancock, D Milligan, G. Vaughan Hudson, Anthony H. Goldstone and S. E. Kinsey and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Annabel McMillan

14 papers receiving 915 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1993 768 citations David C. Linch, A. H. Goldstone et al. The Lancet profile →

Peers

Countries citing papers authored by Annabel McMillan

Since Specialization

Citations

This map shows the geographic impact of Annabel McMillan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annabel McMillan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annabel McMillan more than expected).

Fields of papers citing papers by Annabel McMillan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annabel McMillan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annabel McMillan. The network helps show where Annabel McMillan may publish in the future.

Co-authorship network of co-authors of Annabel McMillan

This figure shows the co-authorship network connecting the top 25 collaborators of Annabel McMillan. A scholar is included among the top collaborators of Annabel McMillan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annabel McMillan. Annabel McMillan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group 2025 ·British Journal of Haematology ·Sally Moore, (unknown), Christopher Parrish, (unknown), Laura Miller, (unknown), (unknown), (unknown), (unknown), Suzanne Thompson, (unknown), John R Jones, Annabel McMillan, Orla McCourt, Charlotte Pawlyn, Hira Mian, Gordon Cook	0
2	Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single center, real-world experience 2024 ·Haematologica ·Ke Xu, (unknown), Nikolaos Kanellias, William Wilson, Annabel McMillan, Xenofon Papanikolaou, Lydia Lee, Rakesh Popat, Jonathan Sive, Neil Rabin, Kwee Yong, Agapi Parcharidou, Charalampia Kyriakou	0
3	Outcomes of melphalan 140 mg/m² followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), William Wilson, (unknown), Rakesh Popat, Ke Xu, Neil Rabin, Jonathan Sive, Xenofon Papanikolaou, Lydia Lee, Annabel McMillan, Kwee Yong, Chara Kyriakou	0
4	Myeloid neoplasm post cytotoxic treatment in patients with multiple myeloma 2024 ·SHILAP Revista de lepidopterología ·Ke Xu, (unknown), (unknown), Elisabeth P. Nacheva, Annabel McMillan, Lydia Lee, Xenofon Papanikolaou, Rakesh Popat, Jonathan Sive, Kwee Yong, Neil Rabin, Charalampia Kyriakou, Rajeev Gupta	0
5	The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study 2024 ·Supportive Care in Cancer ·(unknown), (unknown), (unknown), (unknown), Orla McCourt, Helen Poole, (unknown), Kwee Yong, Rakesh Popat, Lydia Lee, Annabel McMillan, Xenofon Papanikolaou, Ke Xu, Chara Kyriakou, Neil Rabin, (unknown), Abigail Fisher, Jonathan Sive	0
6	The Impact of Continuous Lenalidomide Maintenance Treatment on People Living with Multiple Myeloma - a Single-Centre Qualitative Service Evaluation 2023 ·Blood ·(unknown), (unknown), (unknown), Kwee Yong, Annabel McMillan, (unknown), Xenofon Papanikolaou, Ke Xu, Charalampia Kyriakou, Neil Rabin, Ashutosh Wechalekar, Rakesh Popat, (unknown), Orla McCourt, Helen Poole, (unknown), Abigail Fisher, Jonathan Sive	0
7	Adaptation of a multiple myeloma minimal residual disease multicolor flow cytometry assay for real‐world practice 2022 ·Cytometry Part B Clinical Cytometry ·Annabel McMillan, (unknown), (unknown), (unknown), (unknown), (unknown), Yanping Guo, Kwee Yong, Jonathan Sive	0
8	Antibody-drug conjugates for multiple myeloma 2020 ·Expert Opinion on Biological Therapy ·Annabel McMillan, (unknown), Rakesh Popat	14
9	Scoring system to facilitate diagnosis of Gaucher disease 2020 ·Internal Medicine Journal ·Atul Mehta, Oliver Rivero‐Arias, (unknown), (unknown), Annabel McMillan, (unknown), Jeremy R. Bright, David J. Kuter	8
10	Brentuximab vedotin plus bendamustine in relapsed and refractory classical Hodgkin lymphoma in children, adolescents and young adults: a single centre experience 2020 ·Klinische Pädiatrie ·Annabel McMillan, (unknown), Paul Humphries, Jonathan Lambert, (unknown), (unknown), William Townsend, (unknown), (unknown), KM Ardeshna, Stephen Daw	1
11	Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy 2020 ·British Journal of Haematology ·Rory McCulloch, Carlo Visco, Toby A. Eyre, Rebecca Frewin, Neil Phillips, David Tucker, Francesca Maria Quaglia, Annabel McMillan, Jonathan Lambert, (unknown), Simon Rule	39
12	R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy 2019 ·Blood ·Rory McCulloch, Carlo Visco, Rebecca Frewin, Neil Phillips, Toby A. Eyre, David Tucker, Francesca Maria Quaglia, Annabel McMillan, Jonathan Lambert, (unknown), Simon Rule	4
13	Development of an algorithm to facilitate diagnosis of Gaucher disease 2019 ·Molecular Genetics and Metabolism ·Atul Mehta, Oliver Rivero‐Arias, (unknown), (unknown), Annabel McMillan, David J. Kuter	1
14	IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma 2008 ·British Journal of Haematology ·Christopher P. Fox, Annabel McMillan, Mark Bishton, Alexandria Porcia Haynes, Nigel H. Russell	7
15	Detection and significance of bone marrow infiltration at the time of autologous bone marrow transplantation in Hodgkin's disease 1994 ·British Journal of Haematology ·Rajesh Chopra, AC Wotherspoon, (unknown), Annabel McMillan, Wendy Mills, Adele K. Fielding, D C Linch, A. H. Goldstone	5
16	A NOVEL ISOFORM OF THE LOW-AFFINITY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR 1993 ·UCL Discovery (University College London) ·Stephen Devereux, (unknown), Asim Khwaja, Annabel McMillan, (unknown)	2
17	The place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease 1993 ·Annals of Oncology ·Anthony H. Goldstone, Annabel McMillan	27
18	Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial breakdown → 1993 ·The Lancet ·David C. Linch, A. H. Goldstone, Annabel McMillan, Rajesh Chopra, G. Vaughan Hudson, D.A. Winfield, Barry W. Hancock, D. J. Moir, D Milligan	768
19	Mini‐BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease 1992 ·British Journal of Haematology ·Rajesh Chopra, David C. Linch, Annabel McMillan, (unknown), K.G. Patterson, D. J. Moir, (unknown), P. Cervi, S. E. Kinsey, A. H. Goldstone	55
20	Hodgkin's disease: controversies and challenges for the future. 1992 ·PubMed ·S Tura, George P. Canellos, Anthony P. Goldstone, Dan L. Longo, Annabel McMillan, Walter J. Urba, Pier Luigi Zinzani	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact